Aims : The overall aim is to synthesize the large volume of high quality trial data being published in pleural disease. This includes phase III trials in several sub-specialty areas and updated international guidelines, due to be published in early 2022. Specific learning outcomes for each session will include:
(1) malignant pleural effusion: participants will be able to select the optimal diagnostic strategy, include use of thoracoscopy and direct-to-biopsy approaches, and be able to explain the proven pros and cons of different management options, facilitating patient-centred, evidence-based care
(2) pleural infection: participants will be able to correctly diagnose and identify patients requiring drainage, adjunctive intrapleural therapies and referral for surgery; they will be able to deploy risk prediction scores and understand relevant translational and anti-microbial data
(3) pneumothorax: participants will be able to differentiate between patients requiring admission and those suitable for ambulatory management based on recent phase III trials; they will appreciate the importance of familial pneumothorax and ongoing trials including those involving use of suction.
(4) mesothelioma: participants will be able to select optimal diagnostic and treatment strategies including 1st and 2nd line immunotherapy, the role of regional MDTs and options for early stage disease, including radical surgery and ongoing clinical trials